Moral Economics on Lives Well Lived, by Peter Singer & Kasia de Lazari Radek

 The moral philosophers Peter Singer & Kasia de Lazari Radek interviewed me about Moral Economics on their podcast Lives Well Lived.  At the end, they ask their guests to think about their own life, and to what extent their own life has been well lived.  That's a bit like being asked what you would like to have inscribed on your tombstone.  So I hedged a bit. But the conversation that followed was interesting, so if you scroll down you'll see the transcript of that last bit, which starts about minute 1:09 in the recording.

 Here's the YouTube video of the whole conversation from beginning to end: The moral marketplace with ALVIN ROTH 

  

  
Jun 25, 2026
"Nobel Prize-winning economist Alvin Roth explains how innovative market designs can reduce exploitation and save lives. Drawing on his pioneering work in kidney exchanges, Roth explores some of society’s most contentious moral dilemmas involving organ markets, surrogacy, and unpacks the ethical tensions surrounding what he calls “repugnant transactions.”

 

 Here's the audio link (and the other episodes of Lives Well Lived): https://shows.acast.com/lives-well-lived/episodes/alvin-roth

 

"Lives Well Lived is hosted by Peter Singer & Kasia de Lazari Radek. Episodes consist of interviews with remarkable guests who have lived well, both in the sense of living an ethical life, but also in that they are fulfilled and happy with what they have achieved in their lives. Some of these guests will be well-known figures, but others who are doing extraordinary things will be unfamiliar to almost all of our listeners. The conversations will often cover ground that involves ethics, how to live well, and how to make a positive difference in the world. It will inspire and empower its audience to change their own lives for the better. "

 

Here's the transcript of the last few minutes of the conversation (starting around minute 1:09 of the recording).

PETER: We always asked our guests to think about their own life, and to what extent their own life has been well lived, and by what criteria they make that judgment? Would you like to comment on that, Al? 

 Al: Sure. Has my life been well lived so far?  Well, first, I've had a very fortunate life so far. I am lucky in my family, and my children, and my grandchildren, and my friends. And when you talk about friends, one thing that's often not talked about are the relations that professors have with students. So I've made lifelong friendships with many students who are productively engaged around the world, and that's very gratifying, and I hope it helps make my life worthwhile.

 But also, I'm a market designer, and market design is very outward facing part of, economics. And, one of its goals is, a phrase even older than effective altruism, which is tikkun olam (תִּיקּוּן עוֹלָם) mending the world. And one of the things that market designers try to do is fix markets when they're broken or create them when they're absent. When you think of something like kidney exchange, you know, in a different podcast, on a different subject, I could tell you about victory after victory, where thousands, many thousands of transplants have been done, and lives have been saved through kidney exchange, even though it's in a war that we're losing: the shortage of kidneys is growing faster than the increase in transplants as diabetes grows, and high blood pressure, things like that. So, I would hope that some of my life has looked well lived, not just from the inside, but perhaps also from the outside. 

Peter: Absolutely sure that it has. You're right. And what you've done for kidney markets is just one example, where you've saved many lives, and I think that obviously would be an important part of living well. despite the fact that the problem, as you say, has not been solved as a whole.

Kasia: It must be very satisfying. 

Al: People often say that to me, and it will be satisfying when I'm retired. Right now, it's still frustrating, right? There's so much left to do, and it's not so easy to do it. But the times are changing. In two weeks, I'm gonna be opening up the American Transplant Conference in Boston, and, you know, there are people who invite me to these things.  I sometimes joke with my young colleagues that as the old people who feel a lot of repugnance die off, it'll be left to just us young people. And we'll see.

I was in a transplant conference in Cairo in November. in which we tried to reach consensus on the question of, should countries have to be self sufficient in transplantation, which is the traditional position of the World Health Organization and some other organizations. And, of course, it works against countries that don't have much kidney exchange, because you need a big pool of patient-donor pairs to find lots of exchanges. And in that spirit, incidentally, during COVID, I was in the United Arab Emirates for the first kidney exchange between the UAE and Israel. And, that had to overcome a lot of obstacles, but it makes a lot of sense, because the UAE and Israel each have only a population of about 10 million. And that's not enough to find kidneys in your domestic pool for the hard to match patients, for patients who have a lot of antibodies to human proteins. So, we would like to see much more cooperation and not just between rich countries, but also inviting patients from poor countries, patient-donor pairs, to take part in American kidney exchange. And that's something that remains very controversial, but I think that we might be on the verge of making some progress with that. That's something that Peter has written about also. 

Peter: Yes, I certainly hope so, and because I'm now working as a regular visiting professor in Singapore, which is another small country, the population of about 6 million, there's a very good case for saying that Singapore should also get into international kidney exchanges, and perhaps assist some of the poorer countries in its region. So we're trying to make that argument, and let's hope we succeed. One thing I've tell you, there might be bad news. I don't believe that when you retire from Stanford, you're going to stop working on these issues and be able to relax and feel satisfied, because I know I retired from Princeton 2 years ago, but the issues that I'm concerned about, whether it's the factory farming or global poverty, or all these kidney issues as well, I'm still concerned about, I can't let them go just because I'm no longer paid to be a professor at Princeton.  

#########

 In terms of lives lived well and deeply, here's an earlier post of mine about teachers and students.

Friday, June 7, 2013 Notes on teachers and students from the rabbinical literature

  

 

 

Deceased-donor-initiated kidney-exchange chains are performing well in Italy

 Here's a new report from Italy on initiating kidney exchange chains with a deceased donor.*  In Italy to date, 34 deceased donor initiated chains generated 84 transplants (34 from deceased donors  and 50 from living donors), including 56 among incompatible pairs and 28 to candidates on the waitlist.

Furian L., Di Bella C., Maggiore U., Fiaschetti P., Partelli S., Feltrin G. Integrating Deceased and Living Donation: Long-Term Outcomes of the Italian Deceased-Donor-Initiated Kidney Exchange (DEC-K) Program AJT_ 26/7S1, Volume 26, Issue 7, S1. The cover date will be July 2026. 

"Integrating deceased and living donation through deceased-donor (DD)-initiated chains can expand kidney transplant access in small paired exchange pools. The Italian DEC-K program allocates a DD kidney to initiate a chain (chain-initiating kidney, CIK) among incompatible living-donor (LD) pairs, ultimately returning a LD kidney to the national waiting list (WL). We report the first long-term national results of this donor organ allocation model.
 

"Methods: All DEC-K chains performed in Italy (2018-2025) were retrospectively analyzed. Recipients were stratified by kidney source (CIK vs LD).

...
"Results: Thirty-four DEC-K chains generated 84 transplants (34 DD and 50 LD), including 56 among incompatible pairs and 28 to candidates on the WL. Donor withdrawal occurred once. Four chains were terminated early after CIK transplantation due to newly developed contraindications to donation. At a median follow-up of 60 months, 1- and 3-year graft survival was 100% in both groups, while patient survival was 97.1% for CIK and 98.0% for LD. Three CIK and one LD recipients died with functioning graft (suicide, sepsis, urothelial carcinoma, and acute myocardial infarction, respectively). One CIK recipient experienced graft loss after 40 months due to chronic rejection. Adjusted eGFR trajectories were comparable between CIK and LD (P = 0.48). Chain-ending kidney recipients, with 4 graft loss overall (1 antibody-mediated rejection and 3 vascular thrombosis), showed outcomes comparable to LD (P = 0.64 for eGFR; P = 0.57 for graft survival).
 

"Conclusions: The DEC-K program proved feasible, safe, and effective in expanding transplant opportunities for incompatible and hard-to-match patients."

########

* Some earlier posts on deceased donor initiated chains:

Sunday, April 3, 2022

Kidney Paired Donation Chains Initiated by Deceased Donors

Monday, November 22, 2021

A naturally occurring deceased-donor-initiated kidney exchange chain, by Maghen and Veale

Sunday, August 23, 2020

More on Deceased donors as non‐directed donors in kidney exchange chains

Tuesday, August 7, 2018

Deceased donor chains: Market design language is entering transplantation

Monday, April 11, 2016

Using deceased donor kidneys to start living donor kidney exchange chains

 

Conversations about computing, a podcast by a16Z

  Here's the announcement of a forthcoming series of podcast interviews that looks interesting.:

Announcing First Principles: Rare conversations with the pioneers behind key computing technologies
a16z crypto editorial 

 Here's the trailer:

Financial Times quick review of four new econ books

 The FT has brief reviews of four new economics books:  Moral Economics, The Common Good Economy: A New Compass,  We Need to Tax Billionaires, and Money: The Inside Story

The price of good intentions  Four new books that examine the morals, markets and money behind modern capitalism. by Tej Parikh

Here are the remarks about the one of the four that I'm most familiar with:

      "At a time when public outrage can shape policy decisions faster than ever before, Nobel Prize-winning economist and Stanford professor Alvin Roth makes a compelling case for evidence over instinct in Moral Economics: What Controversial Transactions Reveal About How Markets Work (Basic Books £25/Basic Venture $35). Roth, whose pioneering work in market design transformed systems for kidney donation, examines some of the most contentious exchanges in modern society, including prostitution, organ sales, drugs and medical aid for the dying.

"In the process, Roth delivers some eye-opening hard-truths to those who might think moral intuition ought to underpin all regulation and law. He shows why most policy decisions involve unavoidable moral trade-offs, and how bans of activities deemed objectionable can result in transactions being pushed underground (where they become harder to regulate). He also makes the case for treating markets in distasteful services as moral tools, not failures.

“My goal is not to tell you what to think, but to help you think,” Roth writes in the introduction. He largely succeeds. This is an entertaining and mind-opening read from start to finish. Some may find the discussions about morally “repugnant” topics somewhat offensive — but that’s the point."
 

 

A rogue's gallery of transplant heroes (following ATC2026)

 After my talk yesterday at the American Transplant Congress, I had lunch with a table of transplant heroes, Joe Tector, Peter Friend, Juliana Bastos, Mike Rees and Gustavo Ferreira.

 

 

 

 

 

 

Medical aid in dying (and Moral Economics) on Freakonomics Radio

 The latest episode of Freakonomics looks at the controversies and philosophies involved in the growing legalization of medical aid in dying (MAID).  Stephen Dubner interviews people with multiple perspectives, and offers a personal insight of his own.

"DUBNER: I have a sister who died last year, it was a pretty rotten death, honestly, and she wanted to hasten it. We couldn’t physically orchestrate it. And it really made me see this issue in a new way. It just seemed, you know, I don’t want to say the scales fell from my eyes, but I’d never encountered it first-hand. And it made me think that almost anyone who did encounter it first-hand might have a reckoning, might be in favor of it. But I don’t know, maybe that’s just me. Do you have any sense of how broad the support is for it generally?

ROTH: We’re an aging population, so I think not only do more people have a reason to contemplate their own death, but more people know a peer who’s died, and certainly parents have died, and relatives, you know, siblings and friends. So I would think that anyone who’s seen an agonizing death should at least give some thought to whether we should be legalizing medical aid in dying." 

You can listen or read the transcript at this link:

Who Gets to Choose a “Good Death”?
New York is the latest state to legalize medical aid in dying. Stephen Dubner speaks with the governor who signed the law, a Nobel Prize-winning economist, a death doula — and an ethicist who thinks the very idea is wrong.

 "SOURCES:
Kathy Hochul, governor of New York.
Suzanne O'Brien, death doula, founder of Doulagivers Institute.
Al Roth, economist at Stanford University.
Daniel Sulmasy, physician, philosopher, director of the Kennedy Institute of Ethics at Georgetown University.

RESOURCES:
Moral Economics: From Prostitution to Organ Sales, What Controversial Transactions Reveal About How Markets Work, by Al Roth (2026).
"New York Moves to Allow Terminally Ill People to Die on Their Own Terms," by Grace Ashford (New York Times, 2025).
The Good Death: A Guide for Supporting Your Loved One through the End of Life, by Suzanne O'Brien (2025).
The Future of Assisted Suicide and Euthanasia, by Neil Gorsuch (2009).
EXTRAS:
"Make Me a Match (Update)," by Freakonomics Radio (2023).
 

 

Starzl Lecture: "The Economics of Kidney Exchange," Sunday at the American Transplant Congress in Boston

 I'll be speaking Sunday at the American Transplant Congress, on kidney exchange.  It will be hard to squeeze in all the recent developments in my half hour, including current controversies.

State-of-the-Art Speakers:  Transplantation’s leading luminaries and innovative thinkers will share inspiring research and insights at ATC 2026.  
 
Alvin E. Roth, PhD: 
Thomas E. Starzl State-of-the-Art Lecture: The Economics of Kidney Exchange

Sunday, June 21: 11:00 AM ET 

 

 

 

When people rely on A.I. to avoid ethical challenges

 HBS puts the spotlight on a paper by Alex Chan.

When AI Gives Advice, Employees Rarely Ask Why   Featuring Alex Chan. By Ben Rand

"People increasingly trust AI to make decisions—but research by Alex Chan finds they avoid evaluating the algorithm's rationale if it causes moral discomfort. How can organizations encourage employees to think more critically? "

 

Here's the paper:

Preference for Explanations: Case of Explainable AI
By: Alex Chan   Harvard Business School Working Paper, No. 26-028, November 2025.


Abstract
Participants acted as loan officers deciding whether to approve real $10,000-loans issued by a private U.S. lender using an AI’s default-risk predictions. When explanations revealed that the AI penalized non-White or female borrowers, participants were more likely to override the AI’s profit-maximizing recommendation. When their bonuses depended on repayment, however, they sought predictions but avoided explanations, consistent with willful ignorance; this effect disappeared when explanations were framed as purely financial or demographics were hidden. A secondary experiment reveals a novel bias: participants failed to reason contingently and undervalued explanations even when these complemented private information and improved decision accuracy.
 

A chef makes the case for foie gras, and addresses the concerns regarding animal welfare

I'm no expert on the production of foie gras, but I am glad to see arguments about repugnant transactions and controversial markets that take seriously the concerns of opponents.

The Washington Post has the story.  

Why I’m proud to serve foie gras.  But first, let me take your concerns seriously.   By Bart Hutchins
Bart Hutchins is the chef and owner of Butterworth’s in Washington, D.C.

"There is now a proposed ballot initiative moving through Washington that would ban foie gras entirely. No producing it, no selling or serving it. Fines between $1,000 and $5,000 per violation. License suspension for repeat offenses

...

""I am asking you to not sign the petition. But first I want to do something the other side rarely does, which is to take their concerns seriously.

"Gavage — force-feeding through a tube inserted down a bird’s throat — looks terrible. I know because I have seen it. I understand completely why someone sees footage of it and reacts with horror. If you imagine the same thing done to human beings, it looks like violence.

"But here is what I also know, and what the activists with the megaphones do not know and do not want to know because it would complicate the argument they have decided to make.

...

' A duck’s esophagus, where the gavage tube is inserted, is desensitized, without a gag reflex, and it is capable of swallowing whole crustaceans and scaly fish in the wild. Its windpipe is separate from the esophagus, meaning the gavage process has no impact on breathing. More importantly, this overfeeding is something the bird does naturally. Before their annual migration, ducks gorge — they stuff themselves with excess food. The calories are stored as fat, not only in the liver but in the expanded esophagus. (The verb “gorge” comes from this behavior.) What foie gras farming does is amplify a natural biological process rather than invent a cruel one .

...

"The producer I buy foie gras from exemplifies the kind of care and attention good farming demands. Their ducks are raised for 15 weeks, about twice the poultry industry standard, in open barns, on a vegetarian diet. Force-feeding by hand happens three times a day for the final three weeks. Each feeding takes approximately 1½ seconds, and, from my observation, the ducks barely seem to notice it."   

#######

My previous posts about foie gras. 

  

Horsemeat, Prostitution and Kidney Sales, interview by Peter Coy

 Peter Coy interviewed me about Moral Economics for his substack Economics for Everyone.

You can find the video and the transcript at this link: 

Horsemeat, Prostitution and Kidney Sales  by Peter Coy 
"Nobel laureate Al Roth tackles them all in a fine new book. I interviewed him."

"I asked Roth if he’s a libertarian, since libertarians say people should be free to do what they want as long as it doesn’t hurt others. No, Roth told me.

“People who call themselves libertarians often don’t like market regulation of any sort, but I’m a market designer,” Roth said. “I think that good regulations help markets work well.”

 ############ 

 Peter C. interviewd me once before:

Tuesday, February 6, 2024

Kidney exchange (and other bits of market design) in the New York Times

" Peter Coy, the veteran New York Times economics columnist, writes about kidney exchange, after an interview/conversation sparked by a recent working paper of mine, Market Design and Maintenance. (He's a rare economic journalist who reads economists' papers.)

Here's his column, published yesterday afternoon:

The Economist Who Helped Patients Get New Kidneys, Feb. 5, 2024, 3:00 p.m. ET, By Peter Coy

He's also a rare interviewer: his column includes the names of more of my coauthors than I can recall in any other interview. In order of appearance: Tayfun Sonmez and Utku Unver, Frank Delmonico, Susan Saidman, Mike Rees (implicitly) when he names Mike's nonprofit Alliance for Paired Kidney Donation, and Elliott Peranson.  Market design is, after all, a team sport."

 

European Workshop on Market Design #6, 17 — 18 June 2026, in Paris

 Coming up this week.

European Workshop on Market Design #6

17 — 18 June 2026

• Home
• Outline
• Program
• Venue
• Contact

The 6th edition of the European Workshop on Market Design (2026 EWMD) holds at

Université Panthéon-Sorbonne (Paris 1)
12 Place du Panthéon
75005 Paris,

The 2026 Lecture in Memory of Nora Szech (1980-2023) will be given by Klaus Schmidt (Ludwig-Maximilians-University Munich).

Speakers:

Nageeb Ali, Penn State University

Mira Frick, Princeton University

Guillaume Haeringer, Baruch College

Ilan Kremer, University of Warwick

Philippos Louis, University of Cyprus

Justus Preusser, Bocconi University

Agathe Pernoud, Chicago Booth

Cyril Rouault, GRANEM, University of Angers and Centre for Economics at Paris-Saclay

Anna Sanktjohanser, Toulouse School of Economics

Klaus Schmidt, Ludwig-Maximilians-University Munich

Nikhil Vellodi, Paris School of Economics

Maren Vairo, University of Pennsylvania

Organizing Committee

Nina Bobkova, Rice University

Olivier Bos, ENS Paris-Saclay, Centre for Economics at Paris-Saclay

Nicolas Fugger, University of Cologne & ZEW Mannheim

Daniil Larionov, University of Munster

Marion Ott, ZEW Mannheim

Xiangyu Qu, Unviersity Paris 1 Panthéon-Sorbonne

 

Organ Allocation and Transplantation, by Ashlagi and Roth, forthcoming in Annual Review of Economics 2026

 Here's a  forthcoming review paper on organ allocation and transplantation that focuses on the allocation of deceased-donor organs, particularly kidneys, and goes through the whole supply chain, from donor registration and family consent after death, to patient prioritization, and organ allocation. We also discuss the regulatory and political practices and ethical concerns that keep the availability of transplants far short of their need.

Organ Allocation and Transplantation
by Itai Ashlagi and Alvin E. Roth, Annual Review of Economics   
Vol. 18 https://doi.org/10.1146/annurev-economics-092425-123425
Review in Advance first posted online on June 08, 2026. (Changes may still occur before final publication.)
 
Abstract: There is a large shortage of solid organs for transplants. This survey reviews the allocation of organs (particularly kidneys), with an emphasis on how deceased donor organs are obtained and allocated in the United States but with pointers to related issues involving living donors and transplantation around the world. We review some of the key institutional details and theoretical and empirical studies and describe some open questions that we hope will continue to attract attention from researchers interested in the economic and operational aspects of organ allocation. 

 

The paper ends with a set of open questions and research directions, followed by these concluding paragraphs about the future:

 "THE DAY AFTER TOMORROW

"Efforts to quickly improve the availability of transplants include recovering more transplantable organs from deceased donors, successfully transplanting more of those recovered organs, and facilitating more living donor organ transplants of kidneys and livers. In the longer term, efforts are under way to reduce the need for human organ transplants by reducing the need for re-transplantation (after graft failure) and by preventing organ failure or curing it by other means. 

"It is common to hear that xenotransplantation is tomorrow’s cure for organ failure, and always will be. However, recent developments in transplanting organs from genetically modified pigs into primates and humans suggest that the future possibilities are real, even though (as of this writing) no pig organ transplant to a human has yet survived for as much as a year (although there have now been some pig kidney and heart transplants that worked for months; Tector 2025). Another somewhat related approach involves trying to bioengineer an artificial kidney by removing from a pig kidney the pig cells that would be attacked by the human immune system, leaving a scaffold that could be populated with human kidney cells (Lo et al. 2024). Less developed so far is the hope of regrowing kidneys through some kind of stem cell manipulation, although some kidney cell growth in mice has been achieved (Araoka et al. 2025).
 

"Each of these lines of research offers the possibility of reducing or ending the need for, and hence the scarcity of, human organs for transplantation. That scarcity would also be reduced by medical progress in reducing the incidence and progression of kidney disease and its precursors and of other kinds of organ failure that now require transplantation.  Yet it remains likely that almost everyone whose life could be extended by a human organ transplant today will die without one, and so our attention to the shortage of transplants is still needed." 

Best books of 2026 so far (a small publishing adventure, with pictures)

 At one month post-publication of Moral Economics, I continue to get small bits of feedback.  Here's one, from the editors of Amazon.

Best Business & Leadership Books of 2026 So Far 

 

 Neither first nor last on the list:

 ,,,

And that list is one among many that Amazon compiles:

 

 

With so many best books, I asked Microsoft Copilot for an estimate of total numbers of new books annually, and got this table, which notes that the vast majority of new books are self-published. (I wonder how many are written by A.I....):

 

 

While I'm on the subject, here's a picture a friend sent me from a bookstore in Chicago's OHare airport. (Maybe Moral Economics is an airport book after all:)

 

###########

Afternoon update (this just in, still June 12): It turns out Moral Economics is a Best  Book Club book too:)

 

Euthanasia and hospice care for pets

Medical aid in dying and hospice care are now available for pets too. 

 The New Yorker has the story:

When Should You Say Goodbye to a Pet?
Across the country, the booming industry of pet hospice is teaching people how to face the loss of their beloved companions.
By Sunita Puri 

" In the nineteen-seventies, hospice care evolved as more people resisted the compulsion to extend life at all costs, preferring instead to focus on dying comfortably, often at home. Now caring for a sick pet involved the same questions: What is a good quality of life? How much suffering is too much? And when is the right time to let go?

...

"The concept of pet hospice emerged in the eighties and nineties. In 1994, Amir Shanan, a Chicago-based veterinarian, was asked by a couple to euthanize their beloved dog at home. He started to advertise his work, and more people began calling. Their desire to give their pets a graceful end was so strong that they were willing to invite a stranger into their homes to do it. Shanan was astounded.

"Eventually, pet owners began to tell Shanan that they needed his help well before it was time for euthanasia. “With euthanasia, the focus is on the time of death, and grief after the loss, but there is so much more that happens in the time between a bad diagnosis and death,” Shanan told me. 

...

" In 2009, he founded the International Association for Animal Hospice and Palliative Care, which now has more than fifteen hundred veterinarian-members around the world. Shanan recruited a team that helped him develop guidelines, create a training program for veterinarians, and write an early textbook on the subject, which was published in 2017. The organization believes that dying is “a normal process,” and that its work allows pets and their families “to attain a degree of mental and spiritual preparation for death.”

"Although pet hospice is modelled on human hospice, there are fundamental differences between the two. Human hospice, which is covered by most insurance, involves treating the emotional, spiritual, and physical suffering caused by a terminal illness as it unfolds naturally. Enrollment requires a prognosis of less than six months to live, and euthanasia is never considered. (Some states have legalized medical aid-in-dying, in which patients self-administer a life-ending medication, but euthanasia, in which the medication is administered intravenously by a health-care provider, is illegal in the United States.) "

Will cloned horses end progress in horse breeding?

 The WSJ has the story:

 More Top Horses Are Being Cloned, Rattling the World of Equestrian Sports
"Exact genetic replicas of successful steeds, long popular in polo, are appearing in other disciplines. Some ask: Is it the end of the happy accidents that breed ever-better horses?  By  Alexandra Wexler

"For generations, the world’s top horse breeders have carefully mixed bloodlines for temperament, strength, conformation and athleticism. Each new foal bore the promise of outperforming a carefully chosen set of parents. It isn’t quite natural selection, but it isn’t far off.

"Now the equestrian world might be hitting a plateau: exact genetic replicas of successful horses and ponies. In other words, clones.

...

"Polo player Adolfo Cambiaso, regarded by many in the sport as the greatest of all time, essentially created the sporthorse cloning industry when he made a slew of genetic copies of his best ponies, starting in the early 2000s—and began winning tournaments on them.

"In 2010, a clone of his champion mare Cuartetera sold at auction for $800,000, an eye-popping sum for a polo pony at the time

...

"Cloning is a controversial practice, but particularly so in horse sports. It is banned in thoroughbred racing and competitors in other disciplines are divided, with some saying it creates unrealistic expectations and stifles advances in breeding.

...

"The Fédération Equestre Internationale, the governing body for Olympic horse sports, banned clones from competition in 2007. But it reversed that decision in 2012 after determining they didn’t provide competitors with an unfair advantage, due to the myriad environmental factors that go into producing a champion, like parentage, training, the rider, the type of food it eats and even the shoes it wears. 

...

"Buenos Aires-based Kheiron Biotech, an equine cloning company, produced around 400 cloned horses during the season that ended in February, mostly of various polo ponies. "

########

Clone your pet. 

 

 

Privacy and prices: will A.I. accelerate surveillance pricing?

If A.I. assisted "surveillance pricing" is going to identify you as a high willingness-to-pay consumer, maybe it will be a good idea to train an A.I. shopping agent to impersonate a low willingness-to-pay consumer on your behalf.

The WSJ has the story: 

What Is Personalized Pricing—and Why Are Lawmakers Scrambling to Ban It?
Companies already track your every move online. Some researchers say it is only a matter of time until retailers start using that data to set prices just for you.
By Jackie Snow 

"Businesses have long tracked customers’ search behavior and buying history and used that information, along with other factors like a consumer’s location, to offer promotions and discounts to motivate purchases. Dynamic pricing, where the same fare or rate shifts for everyone based on supply and demand, also has become common across industries, including airfares and ride-shares. What is different now and concerning to researchers is the possibility that online retailers could use personal data to set a higher base price for individual consumers, without their knowledge, when algorithms detect things like urgent need or high disposable income.

...

"It is difficult to find more than isolated cases currently. However, many researchers believe personalized pricing will become increasingly common as the technology to make it possible improves.
...

" Software that automates price-setting—often driven by artificial intelligence—can help retailers seamlessly turn that data into tailored pricing.

"In early 2025, the Federal Trade Commission released initial findings of an investigation into surveillance pricing (another term for personalized pricing). It determined that companies were selling pricing and consumer-data tools to help retailers across various industries set individualized prices—a strong indication to some researchers that retailers were headed in that direction.